SEPTEMBER 2008 — In This Issue:
Finding a Drug's Mechanism of Action
Compound Profiling and Toxicity
Partnership with Pfizer, Diagnostic Development Collaboration with the University of Texas, Biofuel Research with LS9
Science and Technology
Gemin X Pharmaceuticals: Finding a Drug's Mechanism of Action
Gemin X, a pharmaceutical company focused on the discovery and development of advanced oncology therapeutics, approached Metabolon to run a metabolism profile for one of their compounds—GMX1777.
Working with Metabolon's project team, Gemin X designed a simple cell culture time course study to give mechanistic insight into this promising new drug. While previous experimental paradigms utilizing "omics" technologies had been unable to produce conclusive evidence for the mechanism of action of GMX1777, utilizing a global and unbiased approach to biochemical profiling Metabolon and Gemin X were able to easily see pathways impacted strongly and early by GMX1778.
Click here to read the complete case study.
Application Focus
Compound Profiling and Toxicity

The Challenge: Understanding a compound's on and off target activities with associated toxicities and indications
Utilizing a systems approach to drug discovery has generated a multitude of high affinity compounds for various classes of molecular targets with different degrees of disease state validation. As these compounds are progressed to the clinic, they pass through a number of defined assays to determine compound efficacy as well as possible toxicities. Although these assays give substantial information on certain toxicities and mechanism of action, toxic effects as well as mechanistic understanding can be found further downstream in the pre-clinical to clinical stage.
Click here to download the full application note.
Metabolon News
Metabolon Announces Implementation of Metabolomics Platform at Pfizer
mVision To Be Used For Bioprocess Optimization
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today the implementation of its metabolomics technology at Pfizer's Bioprocess R&D Group. This global biochemical profiling technology, called mVision, will provide analysis of samples from bioreactors. Using mVision, Pfizer will be able to rapidly understand cellular metabolism in the biopharmaceutical production process, which in turn will enable Pfizer to optimize bioprocesses and to reduce manufacture costs.
Click here to read the full story.
Metabolon Announces Collaboration with the University of Texas Health Science Center at San Antonio
Partnership to Accelerate Pre-Diabetes Diagnostic Development
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that it is collaborating with Ralph A. DeFronzo, M.D. and colleagues at The University of Texas Health Science Center at San Antonio. The partnership will help drive development of Metabolon's pre-diabetes diagnostic products as well as provide valuable data for insulin resistance and diabetes-related research.
Click here to read the full story.
Metabolon and LS9 Partner to Apply Metabolomics to Biofuel Research and Production
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today that it has reached an agreement to test materials developed by LS9, Inc., a pioneer in the commercial development of hydrocarbon biofuels.
Click here to read the full story.
Upcoming Events
Comments? Questions? We want to hear from you.
Please contact us at info@metabolon.com or visit our website at www.metabolon.com

Services Diagnostics About Us News